Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$71.71 USD
+0.19 (0.27%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $71.76 +0.05 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Company Summary
New York, NY-based Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of the central nervous system, disorders for which there are limited treatment options available.
In August, the FDA approved Auvelity (AXS-05,) for the treatment of adults with major depressive disorder (MDD), making it the first approved drug in Axsome’s portfolio. Axsome launched Auvelity as MDD therapy in the United States in October 2022. AXS-05 is also being investigated for agitation associated with Alzheimer’s disease and smoking cessation.
Company Summary
New York, NY-based Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of the central nervous system, disorders for which there are limited treatment options available.
In August, the FDA approved Auvelity (AXS-05,) for the treatment of adults with major depressive disorder (MDD), making it the first approved drug in Axsome’s portfolio. Axsome launched Auvelity as MDD therapy in the United States in October 2022. AXS-05 is also being investigated for agitation associated with Alzheimer’s disease and smoking cessation.
Other pipeline candidates in the company’s portfolio include AXS-07, AXS-09, AXS-12, and AXS-14, which are being developed for multiple CNS indications.
In April 2022, Axsome received a complete response letter (CRL) for an NDA seeking approval for AXS-07 for the acute treatment of migraine. The company expects to resubmit the NDA in the first half of 2024.
AXS-12 is being studied for the treatment of narcolepsy and AXS-14 (esreboxetine) is currently being developed for the treatment of fibromyalgia. Axsome obtained exclusive U.S. rights for AXS-14 from Pfizer in January 2020.
Axsome completed its acquisition of a commercialized drug targeting narcolepsy, Sunosi, from Jazz in May 2022. In February 2023, Axsome entered a licensing agreement with Pharmanovia to market Sunosi in European and certain Middle East North African countries.
Axsome generated total revenues of $270.6 million in 2023, significantly up year over year.
General Information
Axsome Therapeutics, Inc
One World Trade Center 22nd Floor
NEW YORK, NY 10007
Phone: 212-332-3241
Fax: 212-320-0245
Web: http://axsome.com
Email: NA
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Earnings Date | 5/6/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -1.21 |
Current Year EPS Consensus Estimate | -3.81 |
Estimated Long-Term EPS Growth Rate | NA |
Earnings Date | 5/6/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 71.52 |
52 Week High | 98.40 |
52 Week Low | 55.02 |
Beta | 1.13 |
20 Day Moving Average | 541,975.44 |
Target Price Consensus | 123.33 |
4 Week | -10.38 |
12 Week | -23.47 |
YTD | -10.14 |
4 Week | -6.72 |
12 Week | -25.62 |
YTD | -15.10 |
Shares Outstanding (millions) | 47.37 |
Market Capitalization (millions) | 3,388.22 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 42.97% |
vs. Previous Quarter | 44.70% |
vs. Previous Year | 193.50% |
vs. Previous Quarter | 23.77% |
Price/Book | 17.72 |
Price/Cash Flow | NA |
Price / Sales | 12.52 |
3/31/24 | NA |
12/31/23 | -70.67 |
9/30/23 | -88.79 |
3/31/24 | NA |
12/31/23 | -27.47 |
9/30/23 | -35.35 |
3/31/24 | NA |
12/31/23 | 3.63 |
9/30/23 | 4.46 |
3/31/24 | NA |
12/31/23 | 3.52 |
9/30/23 | 4.38 |
3/31/24 | NA |
12/31/23 | -55.57 |
9/30/23 | -76.46 |
3/31/24 | NA |
12/31/23 | -88.41 |
9/30/23 | -90.33 |
3/31/24 | NA |
12/31/23 | -88.06 |
9/30/23 | -89.75 |
3/31/24 | NA |
12/31/23 | 4.04 |
9/30/23 | 5.71 |
3/31/24 | NA |
12/31/23 | 2.46 |
9/30/23 | 2.66 |
3/31/24 | NA |
12/31/23 | 0.93 |
9/30/23 | 0.66 |
3/31/24 | NA |
12/31/23 | 48.25 |
9/30/23 | 39.70 |